{"component": "definition", "props": {"groups": [{"samples": [{"hash": "j44PL5XGFzC", "uri": "/contracts/j44PL5XGFzC#clinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 27.0068454742, "published": true}, {"hash": "hlS0hCx7HWx", "uri": "/contracts/hlS0hCx7HWx#clinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 26.7494869232, "published": true}, {"hash": "lkKzWGggC3X", "uri": "/contracts/lkKzWGggC3X#clinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 25.3696098328, "published": true}], "snippet": "means the conduct of clinical trials in humans to assess the dosing, safety and/or efficacy of the Product, including but not limited to Phase I Clinical Trials, Phase II Clinical Trials, Phase Ill Clinical Trials and Phase IV Clinical Trials.", "snippet_links": [{"key": "conduct-of-clinical-trials", "type": "clause", "offset": [10, 36]}, {"key": "the-product", "type": "definition", "offset": [95, 106]}, {"key": "not-limited", "type": "clause", "offset": [122, 133]}, {"key": "phase-i-clinical-trials", "type": "definition", "offset": [137, 160]}, {"key": "phase-ii-clinical-trials", "type": "definition", "offset": [162, 186]}, {"key": "phase-iv-clinical-trials", "type": "definition", "offset": [218, 242]}], "size": 17, "hash": "c3953a11109ed9dc616dd742b5d1bd1b", "id": 1}, {"samples": [{"hash": "komvCthxGS7", "uri": "/contracts/komvCthxGS7#clinical-development", "label": "Exclusive Collaboration Agreement (Eikon Therapeutics, Inc.)", "score": 37.0219039917, "published": true}, {"hash": "agTp2dRsUhH", "uri": "/contracts/agTp2dRsUhH#clinical-development", "label": "Exclusive Collaboration Agreement (Eikon Therapeutics, Inc.)", "score": 36.3511276245, "published": true}], "snippet": "means Clinical Studies, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval.", "snippet_links": [{"key": "clinical-studies", "type": "clause", "offset": [6, 22]}, {"key": "report-writing", "type": "clause", "offset": [49, 63]}, {"key": "submission-of", "type": "clause", "offset": [85, 98]}, {"key": "drug-approval-applications", "type": "definition", "offset": [99, 125]}, {"key": "regulatory-affairs", "type": "clause", "offset": [127, 145]}, {"key": "with-respect-to", "type": "clause", "offset": [146, 161]}, {"key": "the-foregoing", "type": "clause", "offset": [162, 175]}, {"key": "other-activities", "type": "definition", "offset": [184, 200]}, {"key": "required-by", "type": "definition", "offset": [258, 269]}, {"key": "regulatory-authority", "type": "definition", "offset": [272, 292]}, {"key": "regulatory-approval", "type": "clause", "offset": [352, 371]}], "size": 8, "hash": "2423c612c951cb896a930591bfbb3089", "id": 2}, {"samples": [{"hash": "l6vqfAjqqBu", "uri": "/contracts/l6vqfAjqqBu#clinical-development", "label": "Supply Agreement (Biomira Inc)", "score": 21.0, "published": true}, {"hash": "e43kYQrlo9a", "uri": "/contracts/e43kYQrlo9a#clinical-development", "label": "Supply Agreement (Biomira CORP)", "score": 21.0, "published": true}, {"hash": "hXCriohQtJK", "uri": "/contracts/hXCriohQtJK#clinical-development", "label": "Agreement and Plan of Reorganization (Biomira Inc)", "score": 19.0, "published": true}], "snippet": "means all activities required for MARKET APPROVAL of PRODUCT in the TERRITORY (including without limitation clinical trials and toxicology studies), as well as all clinical activities desirable for optimized marketing of PRODUCT in the TERRITORY (including without limitation phase IIIb and phase IV studies). This term does not include any activities necessary for manufacture and/or supply of PRODUCT;", "snippet_links": [{"key": "activities-required", "type": "clause", "offset": [10, 29]}, {"key": "approval-of-product", "type": "clause", "offset": [41, 60]}, {"key": "in-the-territory", "type": "clause", "offset": [61, 77]}, {"key": "including-without-limitation", "type": "clause", "offset": [79, 107]}, {"key": "clinical-trials", "type": "clause", "offset": [108, 123]}, {"key": "toxicology-studies", "type": "definition", "offset": [128, 146]}, {"key": "clinical-activities", "type": "definition", "offset": [164, 183]}, {"key": "marketing-of-product", "type": "clause", "offset": [208, 228]}, {"key": "phase-iv-studies", "type": "definition", "offset": [291, 307]}, {"key": "necessary-for", "type": "definition", "offset": [352, 365]}, {"key": "supply-of-product", "type": "clause", "offset": [385, 402]}], "size": 6, "hash": "a50152d68f28d38053720da541fcbd1a", "id": 3}, {"samples": [{"hash": "1YPNKO4QfCa", "uri": "/contracts/1YPNKO4QfCa#clinical-development", "label": "License Agreement (Santarus Inc)", "score": 22.1800136566, "published": true}, {"hash": "imqkaQ57z9n", "uri": "/contracts/imqkaQ57z9n#clinical-development", "label": "License Agreement (Santarus Inc)", "score": 21.8542098999, "published": true}], "snippet": "means all clinical development activities relating to obtaining Regulatory Approval to market and sell Licensed Product for a particular indication, dose or formulation (but not including post-Regulatory Approval activities required by the relevant regulatory authority to support such Regulatory Approval in a country or other post-approval product support clinical trials undertaken by the Parties, including any Phase IV Trials).", "snippet_links": [{"key": "clinical-development-activities", "type": "definition", "offset": [10, 41]}, {"key": "relating-to", "type": "definition", "offset": [42, 53]}, {"key": "obtaining-regulatory-approval", "type": "clause", "offset": [54, 83]}, {"key": "licensed-product", "type": "clause", "offset": [103, 119]}, {"key": "required-by", "type": "definition", "offset": [224, 235]}, {"key": "authority-to", "type": "clause", "offset": [260, 272]}, {"key": "other-post", "type": "clause", "offset": [322, 332]}, {"key": "product-support", "type": "clause", "offset": [342, 357]}, {"key": "clinical-trials", "type": "clause", "offset": [358, 373]}, {"key": "by-the-parties", "type": "clause", "offset": [385, 399]}, {"key": "phase-iv", "type": "clause", "offset": [415, 423]}], "size": 6, "hash": "bf37879de855c6c0e932681ccce9ffc6", "id": 4}, {"samples": [{"hash": "3eJwoHYy3nj", "uri": "https://www.legislation.gov.uk/uksi/2016/190/data.pdf", "label": "www.legislation.gov.uk", "score": 11.0479125977, "published": false}, {"hash": "aCDiW4kMo94", "uri": "https://d353ahjsg66ro4.cloudfront.net/cy/uksi/2016/190/data.pdf", "label": "d353ahjsg66ro4.cloudfront.net", "score": 10.8165636063, "published": false}, {"hash": "2o8NS1nU7C5", "uri": "https://www.legislation.gov.uk/uksi/2012/504/2013-03-31/data.pdf?view=extent", "label": "www.legislation.gov.uk", "score": 10.3483915329, "published": false}], "snippet": "means the conduct of studies of a medicinal product in human subjects in order to\u2014", "snippet_links": [{"key": "conduct-of-studies", "type": "clause", "offset": [10, 28]}, {"key": "medicinal-product", "type": "clause", "offset": [34, 51]}, {"key": "in-human-subjects", "type": "clause", "offset": [52, 69]}, {"key": "in-order-to", "type": "clause", "offset": [70, 81]}], "size": 5, "hash": "295396822647897b69633230973a3a4f", "id": 5}, {"samples": [{"hash": "Q2QFJpa3hi", "uri": "/contracts/Q2QFJpa3hi#clinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.2217655182, "published": true}, {"hash": "kayjChU2uZp", "uri": "/contracts/kayjChU2uZp#clinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.2108154297, "published": true}, {"hash": "6rYmvPxNCPe", "uri": "/contracts/6rYmvPxNCPe#clinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.164270401, "published": true}], "snippet": "means all Development activities in humans for a Candidate or Product undertaken from and after Initiation of the first Phase I Clinical Trial for such Candidate or Product, including conduct of each Clinical Trial.", "snippet_links": [{"key": "development-activities", "type": "clause", "offset": [10, 32]}, {"key": "initiation-of-the", "type": "clause", "offset": [96, 113]}, {"key": "phase-i-clinical-trial", "type": "definition", "offset": [120, 142]}, {"key": "conduct-of", "type": "clause", "offset": [184, 194]}], "size": 4, "hash": "60b5d911d755b7719999d76f377849cb", "id": 6}, {"samples": [{"hash": "eWH5JjoMsus", "uri": "/contracts/eWH5JjoMsus#clinical-development", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 29.0465431213, "published": true}, {"hash": "dNMpYVvBdUT", "uri": "/contracts/dNMpYVvBdUT#clinical-development", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 28.9890480042, "published": true}, {"hash": "a2rdzhz32JX", "uri": "/contracts/a2rdzhz32JX#clinical-development", "label": "License and Collaboration Agreement (Menlo Therapeutics, Inc.)", "score": 28.9260787964, "published": true}], "snippet": "or \u201cClinically Develop\u201d means all Development activities which are directed to the preparation for, conduct of, and analysis of a clinical trial or study of the Product, including, without limitation, as applicable, preclinical testing, toxicology, the examination of particular patient sub-populations within a given indication, and regulatory affairs which do not relate specifically to manufacturing of the Product (including preparation and submission of Regulatory Materials but excluding the Chemistry Manufacturing and Controls related portions of an such Regulatory Materials).", "snippet_links": [{"key": "clinically-develop", "type": "definition", "offset": [4, 22]}, {"key": "development-activities", "type": "clause", "offset": [34, 56]}, {"key": "directed-to", "type": "definition", "offset": [67, 78]}, {"key": "preparation-for", "type": "clause", "offset": [83, 98]}, {"key": "conduct-of", "type": "clause", "offset": [100, 110]}, {"key": "clinical-trial-or-study", "type": "clause", "offset": [130, 153]}, {"key": "without-limitation", "type": "clause", "offset": [181, 199]}, {"key": "the-examination", "type": "clause", "offset": [249, 264]}, {"key": "regulatory-affairs", "type": "clause", "offset": [334, 352]}, {"key": "manufacturing-of-the-product", "type": "clause", "offset": [389, 417]}, {"key": "submission-of", "type": "clause", "offset": [445, 458]}, {"key": "regulatory-materials", "type": "definition", "offset": [459, 479]}, {"key": "but-excluding", "type": "clause", "offset": [480, 493]}], "size": 4, "hash": "2d062c8bb2e5e3a815e872986fd23897", "id": 7}, {"samples": [{"hash": "awmp19vUX5u", "uri": "/contracts/awmp19vUX5u#clinical-development", "label": "Special Products Master Agreement (AbbVie Inc.)", "score": 24.0034217834, "published": true}, {"hash": "dLI5DUDanrk", "uri": "/contracts/dLI5DUDanrk#clinical-development", "label": "Special Products Master Agreement (AbbVie Inc.)", "score": 23.6748809814, "published": true}, {"hash": "1ICpe31Whkv", "uri": "https://investors.abbvie.com/static-files/76fa0d25-1cb4-410a-aa51-824b401a3407", "label": "Amendment", "score": 13.9637231827, "published": false}], "snippet": "means those pre-clinical and clinical activities, including post Regulatory Approval studies that are necessary or reasonably useful to obtain or maintain Regulatory Approval for a product for an indication, including testing in animals for purposes of obtaining or maintaining a Regulatory Approval.", "snippet_links": [{"key": "clinical-activities", "type": "definition", "offset": [29, 48]}, {"key": "regulatory-approval", "type": "clause", "offset": [65, 84]}, {"key": "for-purposes-of", "type": "clause", "offset": [237, 252]}], "size": 4, "hash": "2b6c78a39e60fe79ee9de1aa64558ee5", "id": 8}, {"samples": [{"hash": "gVMLIdOwLMN", "uri": "/contracts/gVMLIdOwLMN#clinical-development", "label": "Option and License Agreement (Quark Pharmaceuticals Inc)", "score": 21.8952770233, "published": true}, {"hash": "8oZ2rg6kIQz", "uri": "/contracts/8oZ2rg6kIQz#clinical-development", "label": "Collaboration Agreement (Quark Pharmaceuticals Inc)", "score": 21.8952770233, "published": true}, {"hash": "gKrzEycCs2d", "uri": "/contracts/gKrzEycCs2d#clinical-development", "label": "Collaboration Agreement (Quark Biotech Inc)", "score": 21.0, "published": true}], "snippet": "means the trials conducted in human subjects to determine the safety, efficacy and pharmacokinetics of a compound as required by the US FDA. Clinical Development includes Phase I, Phase II, Phase III (and IV if required), and the New Drug Application (NDA) for Regulatory Approval by the FDA .", "snippet_links": [{"key": "in-human-subjects", "type": "clause", "offset": [27, 44]}, {"key": "the-safety", "type": "clause", "offset": [58, 68]}, {"key": "as-required-by", "type": "clause", "offset": [114, 128]}, {"key": "us-fda", "type": "definition", "offset": [133, 139]}, {"key": "phase-iii", "type": "definition", "offset": [190, 199]}, {"key": "if-required", "type": "definition", "offset": [208, 219]}, {"key": "new-drug-application", "type": "definition", "offset": [230, 250]}, {"key": "approval-by", "type": "clause", "offset": [272, 283]}, {"key": "the-fda", "type": "clause", "offset": [284, 291]}], "size": 4, "hash": "c15e608a65ccc73a318a4f7c81551848", "id": 9}, {"samples": [{"hash": "gTbyO0nJgNO", "uri": "/contracts/gTbyO0nJgNO#clinical-development", "label": "Collaboration Agreement (Momenta Pharmaceuticals Inc)", "score": 28.0910339355, "published": true}, {"hash": "k3lrvH2DiTw", "uri": "/contracts/k3lrvH2DiTw#clinical-development", "label": "Collaboration Agreement (Momenta Pharmaceuticals Inc)", "score": 27.6666660309, "published": true}, {"hash": "8RjAAnABeHJ", "uri": "/contracts/8RjAAnABeHJ#clinical-development", "label": "Collaboration Agreement (Momenta Pharmaceuticals Inc)", "score": 27.3436012268, "published": true}], "snippet": "means any and all Development activities to be conducted in humans related to or in furtherance of Regulatory Approval, including all clinical trials and any such post-approval regulatory commitments, or Post-Approval Clinical Trials. The Clinical Development activities to be performed as part of the Collaboration shall be as described in the applicable Product Work Plan.", "snippet_links": [{"key": "related-to", "type": "definition", "offset": [67, 77]}, {"key": "regulatory-approval", "type": "clause", "offset": [99, 118]}, {"key": "clinical-trials", "type": "clause", "offset": [134, 149]}, {"key": "regulatory-commitments", "type": "clause", "offset": [177, 199]}, {"key": "activities-to-be-performed", "type": "clause", "offset": [260, 286]}, {"key": "the-collaboration", "type": "clause", "offset": [298, 315]}, {"key": "product-work-plan", "type": "definition", "offset": [356, 373]}], "size": 4, "hash": "0b172d5e86367b92057af9e68fd9a406", "id": 10}], "next_curs": "CmESW2oVc35sYXdpbnNpZGVyY29udHJhY3Rzcj0LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIdY2xpbmljYWwtZGV2ZWxvcG1lbnQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Clinical Development", "snippet": "means the conduct of clinical trials in humans to assess the dosing, safety and/or efficacy of the Product, including but not limited to Phase I Clinical Trials, Phase II Clinical Trials, Phase Ill Clinical Trials and Phase IV Clinical Trials.", "size": 168, "id": "clinical-development", "examples": ["The Clinical Research Plan will include: (a) a description of the Research Program Activities and each Party\u2019s obligations in connection therewith; (b) the projected timelines for completion of the Research Program Activities; (c) an estimated budget for the <strong>Clinical Development</strong> activities (the \u201c<strong>Clinical Development</strong> Budget\u201d); and (d) a clinical trial synopsis with respect to the Clinical Study.", "Moderna may terminate this Project Agreement in the event that Immatics\u2019 has given notice to Moderna pursuant to Section 8.2.2 that the anticipated <strong>Clinical Development</strong> Costs for a given Calendar Year are [***], and the Parties are unable to agree on a mitigation strategy within [***] of such notice.", "The Parties will execute a pharmacovigilance agreement (the \u201cPharmacovigilance Agreement\u201d) by the earlier of: (a) [***] following the Effective Date; and (b) [***] prior to the initiation of <strong>Clinical Development</strong> activities under the Clinical Research Plan, to ensure the exchange of relevant safety data within appropriate timeframes and in an appropriate format to enable the Parties to fulfill local and international regulatory reporting obligations and to facilitate appropriate safety reviews.", "Subject to Section 8.2.2, Moderna shall be responsible for all <strong>Clinical Development</strong> Research Program Costs incurred by either Party in connection with <strong>Clinical Development</strong> Research Program Activities under the Clinical Research Plan.", "For clarity, In no event shall Immatics be required to incur any <strong>Clinical Development</strong> Research Program Costs that are not reimbursed by Moderna, and in no event shall Moderna be required to reimburse Immatics for any <strong>Clinical Development</strong> Research Program Costs that [***].", "Each [***], Immatics shall provide Moderna with a rolling budget forecast for [***], plus an estimate for the overall budget for the <strong>Clinical Development</strong> Budget."], "related": [["commercial-development", "Commercial Development", "Commercial Development"], ["infill-development", "Infill development", "Infill development"], ["initial-development-plan", "Initial Development Plan", "Initial Development Plan"], ["commercial-development-plan", "Commercial Development Plan", "Commercial Development Plan"], ["experimental-development", "experimental development", "experimental development"]], "related_snippets": [], "updated": "2026-03-07T04:27:53+00:00"}, "json": true, "cursor": ""}}